Ann: Presentation at NWR Virtual Healthcare Conference, page-24

The manufacturing cost per patient is typically between US$100,000 and $250,000. However, the final commercial price of CAR-T therapy (including R&D, clinical trials, and profit margins) is significantly higher, often ranging from US$373,000 to $500,000+ per treatment in the U.S. (e.g., Kymriah, Yescarta, and Abecma).

Maybe CHM don’t have the full benefit of economies of scale for cart manufacturing as other companies but reality is they are following GMP protocol and the carts are manufactured in a specialised and accredited facility (outsourced). So I don’t think AU750k is correct